波洛克萨默188的心脏保护是通过增加内皮氧化产生的介导
Gaoxian Chen1,2, Hunter F Douglas3, Zhu Li3
1Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA, USA.
Scientific reports
|April 30, 2025
概括
波洛克萨默188 (P188) 通过增加氧化 (NO) 生产来保护心脏细胞免受缺血/反损伤,这是一种新发现,可以增强内皮细胞功能,并保留大鼠模型中的心脏功能.
科学领域:
- 心血管生物学 心血管生物学
- 再生医学是一种再生医学.
- 生物材料科学 生物材料科学
背景情况:
- 缺血/反 (I/R) 损伤是心脏病发病率和死亡率的主要原因之一.
- 波洛克萨默188 (P188) 是I / R损伤的潜在治疗剂,但其机制,特别是关于内皮细胞和氧化 (NO) 的机制,尚未完全理解.
研究的目的:
- 研究P188在I/R损伤中的心脏保护机制,重点关注内皮细胞功能和NO生产.
- 评估P188在体外人类诱导多能干细胞 (iPSC) 衍生模型和外生老鼠心脏模型中的疗效.
主要方法:
- 利用iPSC衍生的心肌细胞 (CMs) 和内皮细胞 (ECs) 来评估P188在模拟I/R条件下对细胞活力,CM收缩性和EC NO分泌的影响.
- 采用了一种孤立的小鼠心脏模型,接受了I/R损伤,以评估P188对心脏功能和NO生产的影响,有或没有NO抑制.
主要成果:
- P188显著改善了CM存活率和收缩功能,并在iPSC-EC中显著增加了NO分泌.
- 在老鼠心脏中,P188在再注射期间的使用改善了心脏功能,并减少了损伤标志物,这种效应被NO抑制消除了.
- 在非缺血性大鼠心脏中,P188显示了NO产量的剂量依赖性增加.
结论:
- P188通过一种关键的机制,包括增强的氧化 (NO) 生产,对I/R损伤进行心脏保护.
- 这项研究揭示了NO在调解P188在细胞和器官层面的保护作用中的新作用.
- 作为I / R损伤的治疗剂,P188显示出有前途,需要进一步的临床研究.
相关概念视频
01:28Nitric Oxide Signaling Pathway
4.8K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
4.8K
01:16Antianginal Drugs: Nitrates and β-Blockers
432
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
432
01:23Antihypertensive Drugs: Vasodilators
426
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
426
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
01:17Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97